|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCAM1 |
Gene summary for NCAM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCAM1 | Gene ID | 4684 |
| Gene name | neural cell adhesion molecule 1 | |
| Gene Alias | CD56 | |
| Cytomap | 11q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P13591 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4684 | NCAM1 | HTA12-15-2 | Human | Pancreas | PDAC | 3.78e-09 | 4.76e-01 | 0.2315 |
| 4684 | NCAM1 | HTA12-23-1 | Human | Pancreas | PDAC | 1.57e-10 | 8.53e-01 | 0.3405 |
| 4684 | NCAM1 | HTA12-25-1 | Human | Pancreas | PDAC | 2.41e-10 | 6.97e-01 | 0.313 |
| 4684 | NCAM1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.16e-37 | 1.25e+00 | 0.3728 |
| 4684 | NCAM1 | HTA12-29-1 | Human | Pancreas | PDAC | 7.74e-63 | 1.14e+00 | 0.3722 |
| 4684 | NCAM1 | HTA12-30-1 | Human | Pancreas | PDAC | 3.91e-06 | 1.17e+00 | 0.3671 |
| 4684 | NCAM1 | HTA12-32-1 | Human | Pancreas | PDAC | 4.65e-02 | 6.00e-01 | 0.3624 |
| 4684 | NCAM1 | PTC04 | Human | Thyroid | PTC | 1.27e-03 | -7.65e-02 | 0.1927 |
| 4684 | NCAM1 | ATC09 | Human | Thyroid | ATC | 3.63e-03 | 2.88e-01 | 0.2871 |
| 4684 | NCAM1 | ATC1 | Human | Thyroid | ATC | 1.02e-03 | 4.03e-01 | 0.2878 |
| 4684 | NCAM1 | ATC2 | Human | Thyroid | ATC | 1.48e-07 | 7.14e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032113 | Thyroid | PTC | viral process | 236/5968 | 415/18723 | 2.48e-26 | 8.24e-24 | 236 |
| GO:0019058113 | Thyroid | PTC | viral life cycle | 167/5968 | 317/18723 | 8.87e-15 | 5.89e-13 | 167 |
| GO:0044403113 | Thyroid | PTC | biological process involved in symbiotic interaction | 151/5968 | 290/18723 | 5.83e-13 | 2.85e-11 | 151 |
| GO:0051701113 | Thyroid | PTC | biological process involved in interaction with host | 109/5968 | 203/18723 | 8.64e-11 | 2.99e-09 | 109 |
| GO:0052126113 | Thyroid | PTC | movement in host environment | 91/5968 | 175/18723 | 2.41e-08 | 5.43e-07 | 91 |
| GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
| GO:000740918 | Thyroid | PTC | axonogenesis | 178/5968 | 418/18723 | 2.17e-06 | 2.91e-05 | 178 |
| GO:0044409113 | Thyroid | PTC | entry into host | 72/5968 | 151/18723 | 3.48e-05 | 3.29e-04 | 72 |
| GO:0046718112 | Thyroid | PTC | viral entry into host cell | 68/5968 | 144/18723 | 8.26e-05 | 7.00e-04 | 68 |
| GO:0071679 | Thyroid | PTC | commissural neuron axon guidance | 8/5968 | 11/18723 | 6.50e-03 | 2.83e-02 | 8 |
| GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
| GO:001905835 | Thyroid | ATC | viral life cycle | 173/6293 | 317/18723 | 9.22e-15 | 5.50e-13 | 173 |
| GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
| GO:005170134 | Thyroid | ATC | biological process involved in interaction with host | 112/6293 | 203/18723 | 1.93e-10 | 5.76e-09 | 112 |
| GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
| GO:000740919 | Thyroid | ATC | axonogenesis | 197/6293 | 418/18723 | 5.09e-09 | 1.13e-07 | 197 |
| GO:005212633 | Thyroid | ATC | movement in host environment | 94/6293 | 175/18723 | 3.20e-08 | 6.00e-07 | 94 |
| GO:004440933 | Thyroid | ATC | entry into host | 76/6293 | 151/18723 | 1.54e-05 | 1.43e-04 | 76 |
| GO:004671833 | Thyroid | ATC | viral entry into host cell | 72/6293 | 144/18723 | 3.38e-05 | 2.80e-04 | 72 |
| GO:00074113 | Thyroid | ATC | axon guidance | 96/6293 | 227/18723 | 3.74e-03 | 1.63e-02 | 96 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | ADJ |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | Cervix | ADJ |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | Healthy |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | Cervix | Healthy |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | Precancer |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | Cervix | Precancer |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | CRC | ADJ |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | CRC | ADJ |
| NCAM1 | NCAM2 | NCAM1_NCAM2 | NCAM | CRC | ADJ |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | CRC | CRC |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | CRC | CRC |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | CRC | FAP |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | CRC | FAP |
| NCAM1 | NCAM2 | NCAM1_NCAM2 | NCAM | CRC | FAP |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | CRC | MSI-H |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | CRC | MSI-H |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Endometrium | ADJ |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | Endometrium | ADJ |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Endometrium | AEH |
| NCAM1 | NCAM1 | NCAM1_NCAM1 | NCAM | Endometrium | AEH |
| Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCAM1 | SNV | Missense_Mutation | novel | c.942N>C | p.Glu314Asp | p.E314D | protein_coding | tolerated(0.15) | possibly_damaging(0.496) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| NCAM1 | SNV | Missense_Mutation | c.1503G>C | p.Glu501Asp | p.E501D | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NCAM1 | SNV | Missense_Mutation | c.550G>A | p.Glu184Lys | p.E184K | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NCAM1 | SNV | Missense_Mutation | c.2560G>C | p.Glu854Gln | p.E854Q | protein_coding | tolerated(0.07) | possibly_damaging(0.5) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| NCAM1 | SNV | Missense_Mutation | rs370003415 | c.1789N>A | p.Val597Ile | p.V597I | protein_coding | tolerated(0.51) | benign(0.054) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| NCAM1 | SNV | Missense_Mutation | novel | c.43N>A | p.Gly15Arg | p.G15R | protein_coding | tolerated(0.06) | benign(0.108) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NCAM1 | SNV | Missense_Mutation | rs542274622 | c.2083N>A | p.Val695Ile | p.V695I | protein_coding | tolerated(0.5) | benign(0.033) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NCAM1 | SNV | Missense_Mutation | c.431C>G | p.Ser144Cys | p.S144C | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | ||
| NCAM1 | insertion | Frame_Shift_Ins | novel | c.2117_2118insCAGGTGTGTGGCACCACGCCCAGCTAATTTT | p.Glu707ArgfsTer11 | p.E707Rfs*11 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
| NCAM1 | insertion | In_Frame_Ins | novel | c.2082_2083insTTATTTTCAAGAACACAATTAAGAAAAACAAAAAAAAGGAAA | p.His694_Val695insLeuPheSerArgThrGlnLeuArgLysThrLysLysArgLys | p.H694_V695insLFSRTQLRKTKKRK | protein_coding | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CART-56 cells | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CHEMBL2109634 | ONCOLYSIN S | ||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CD56 CAR T cells | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CHEMBL1743037 | LORVOTUZUMAB MERTANSINE | ||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | LORVOTUZUMAB | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | duloxetine | DULOXETINE | 28696415 | |
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | IMGN901 | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CAR-T cells targeting CD56 | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | FGLL | |||
| 4684 | NCAM1 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CD56-specific gene-engineered T cells |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |